Two ACEs in the pack

A genomics-based approach has uncovered the first human homologue of ACE (angiotensin-converting enzyme).

September 28, 2000

A study published in the online version of Circulation Research describes the discovery of ACE-related carboxypeptidase (ACE2) — the first human homologue of the protein ACE (angiotensin-converting enzyme). ACE2 was identified by scientists at Millennium Pharmaceuticals in Massachusetts, and is significant because it is restricted to the heart, kidneys and testes, potentially offering a specific target for drug treatment of hypertension and congestive heart failure.

ACE2 was identified during Millennium's ongoing search for novel genes related to heart failure, which involves sequencing thousands of tissue biopsies from its 'human heart failure ventricle' cDNA library. ACE and ACE2 have only 42% similarity; ACE2 is not inhibited by lisinopril or captopril, and produces an angiotensin peptide whose function is currently unknown. "The organ and cell-specific expression of ACE2 and its unique cleavage of key vasoactive peptides suggest an essential role for ACE2 in the local renin–angiotensin system of the heart and kidney," the researchers conclude. Millennium is now working with Eli Lilley to pursue the development of drugs targeted at ACE2 for the treatment of heart failure.

Popular Now

  1. Genetic Test Solves Royal Mystery
    Notebook Genetic Test Solves Royal Mystery

    Genetic analyses lay to rest conspiracy theories about death of Belgian King Albert I, who lost his life in a rock climbing accident more than 80 years ago.

  2. Investigation Finds Pathologist Guilty of Systemic Misconduct
  3. Bacteria and Humans Have Been Swapping DNA for Millennia
  4. Curious George
    Profile Curious George

    George Church has consistently positioned himself at genomics’ leading edge.